A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Drug manufacturer Eli Lilly has announced their new daily pill may be as effective in lowering blood sugar and aiding weight ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Initially developed to manage blood sugar levels in diabetic patients, GLP-1 agonists have gained popularity for their weight-reducing effects.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Doctors and patients have been hoping for a pill version that would be easier to take, in contrast to an injectable.

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...